

Supplementary Online Content

Costain G, Walker S, Marano M, et al. Genome sequencing as a diagnostic test in children with unexplained medical complexity. *JAMA Netw Open*. 2020;3(9):e2018109. doi:10.1001/jamanetworkopen.2020.18109

eFigure 1. Total Count of HPO Terms for the Proband Cohort (n=49), by Phenotype Category

eFigure 2. Total Number of Probands With at Least One HPO Term in a Phenotype Category

eFigure 3. Total Count of Clinical Genetic Tests in Each Category Performed in the Proband Cohort (n=49)

eFigure 4. Total Number of Probands With at Least One Test in a Clinical Genetic Test Category

eFigure 5. Mean Depth of Coverage of the Genome Sequencing Data

eFigure 6. Median Count of Features by HPO Category in the Diagnosed and Undiagnosed Subgroups


eTable 1. Individuals With Suspected or Partial Primary Diagnoses Known at the Time of Study Recruitment

eTable 2. Demographic and Clinical Features in the Proband Study Cohort


eTable 3. Selected Variants of Uncertain Diagnostic Significance Identified in the Proband Study Cohort

This supplementary material has been provided by the authors to give readers additional information about their work.


eFigure 1. Total Count of HPO Terms for the Proband Cohort (n=49), by Phenotype Category




eFigure 2. Total Number of Probands With at Least One HPO Term in a Phenotype Category




eFigure 3. Total Count of Clinical Genetic Tests in Each Category Performed in the Proband Cohort (n=49)




eFigure 4. Total Number of Probands With at Least One Test in a Clinical Genetic Test Category



eFigure 5. Mean Depth of Coverage of the Genome Sequencing Data



eFigure 6. Median Count of Features by HPO Category^a in the Diagnosed and Undiagnosed Subgroups



^aThe categories “Hematologic”, “Immune System”, “Connective Tissue”, and “Endocrine / Metabolism” are not displayed because the median count was 0 in both subgroups.

eTable 1. Individuals With Suspected or Partial Primary Diagnoses Known at the Time of Study Recruitment

<i>Study ID</i>	<i>Sex</i>	<i>Gene</i>	<i>Condition (MIM # Phenotype)</i>	<i>IP</i>	<i>Variant Details (Zygosity) [Transcript]</i>	<i>Origin</i>	<i>Reasons for further genetic testing</i>
CMC 02	M	-	Down syndrome (190685)	-	47,XY,+21	dn	Severity of developmental delays, seizure disorder, and feeding difficulties
CMC 23	F	<i>HNF4A</i>	Fanconi renotubular syndrome 4, with maturity-onset diabetes of the young (616026)	AD	c.187C>T / p.(R63W) (het) [NM_175914]	pat	Multiple major congenital anomalies
CMC 32	M	<i>SOX5</i>	Lamb-Shaffer syndrome (616803)	AD	c.928T>A / p.(C310S) (het) (NM_006940)	dn	Type I transferrin isoform profile, and variant not classified as pathogenic
CMC 43	M	<i>KRAS</i>	Noonan syndrome 3 (609942)	AD	c.40G>A / p.(V14I) (het) [NM_004985]	dn	Treatment-resistant hyperkinetic movement disorder
CMC 46	M	<i>ATP6AP2</i>	Mental retardation, X-linked, syndromic, Hedera type (300423)	XL	c.301-11_301-10delTT / p.(?) (hem) [NM_005765]	dn	Inflammatory bowel disease, and variant not classified as pathogenic
CMC 49	M	<i>EDA</i>	Ectodermal dysplasia 1, hypohidrotic, X- linked (305100)	XL	c.458G>A / p.(R153H) (hem) [NM_001005612]	mat	Multiple major congenital anomalies

AD, autosomal dominant; dn, *de novo*; F, female; hem, hemizygous; het, heterozygous; IP, inheritance pattern; M, male; mat, maternal; MIM, Mendelian Inheritance in Man® (www.omim.org); pat, paternal; XL, X-linked

eTable 2. Demographic and Clinical Features in the Proband Study Cohort

	Total (n=49)		Diagnosed by GS (n=15)		No diagnosis by GS (n=34)		p-value^a
	Number	(%)	Number	(%)	Number	(%)	
Male sex	29	(59.1)	7	(46.6)	22	(64.7)	ns
Clinical ES	33	(67.3)	9	(60.0)	24	(70.5)	ns
Positive family history ^b	6	(12.2)	3	(20.0)	3	(8.8)	ns
Parental consanguinity	5	(10.2)	2	(13.3)	3	(8.8)	ns
European/Caucasian ethnicity	26	(53.0)	8	(53.3)	18	(52.9)	ns
	Median	(range)	Median	(range)	Median	(range)	
Age in years	6.9	(0.6-17.8)	8	(4.5-17.8)	4.9	(0.6-13.2)	0.003
Coded HPO terms ^c	24	(6-58)	26	(11-45)	23	(6-58)	ns

ES, exome sequencing; GS, genome sequencing; HPO, Human Phenotype Ontology; ns, not significant (p>0.05)

^aFisher's exact test for comparison of proportions, and Kruskal–Wallis test for comparison of medians.

^bFirst-degree relative with at least partial phenotypic overlap

^cSee text for details.

eTable 3. Selected Variants of Uncertain Diagnostic Significance Identified in the Proband Study Cohort

<i>Study ID</i>	<i>Sex</i>	<i>Selected Features</i>	<i>Gene</i>	<i>Variant Details (Zygosity) [Transcript]</i>	<i>Origin</i>
<i>Known disease genes</i>					
CMC 01	F	Congenital microcephaly, GDD/ID, seizures	<i>MED23</i>	c.3957+5G>A (hom) [NM_015979]	mat/pat
CMC 03	F	SMMCI	<i>CDON</i>	c.2674G>A / p.(G892S) (het) [NM_016952]	mat ^a
CMC 04	M	GDD/ID, seizures, hypotonia, structural CNS anomalies	<i>PLCB1</i>	c.246+197G>A (hom) [NM_015192]	mat/pat
CMC 07	F	GDD, hypotonia, structural CNS anomalies	<i>KIF1A</i>	c.4566-66C>T (het) [NM_004321]	dn
CMC 28	M	GDD/ID, seizures, microcephaly, congenital anomalies	<i>THOC2</i>	c.623A>G / p.(N208S) (hem) [NM_001081550]	mat
CMC 29	M	GDD, congenital heart disease	<i>CTBP1</i>	c.107G>A / p.(R36Q) (het) [NM_001328] ^b	dn
CMC 31	M	Intracranial hemorrhage, congenital cataracts	<i>JAM3</i>	c.410-1G>A (het) [NM_032801]	mat
				c.256+1260G>C (het) [NM_032801]	pat
CMC 37	M	Potter sequence, GDD	<i>POLA1</i>	c.3835T>G / p.(F1279V) (hem) [NM_016937]	mat
CMC 50	F	GDD, MCA	<i>TLK2</i>	c.532-1571_831+4del (het) [NM_006852] ^c	uk ^d
<i>Genes not yet associated with a Mendelian disorder</i>					
CMC 04	M	GDD/ID, seizures, structural CNS anomalies	<i>MAGEE1</i>	c.877_984del / p.(293_328del) (hem) [NM_020932]	dn
CMC 18	F	GDD, MCA, nystagmus	<i>SF3B3</i>	c.2012A>G / p.(N671S) (het) [NM_012426]	dn
CMC 26	M	Severe achalasia	<i>ANKRD13B</i>	c.1761C>G / p.(D587E) (het) [NM_152345]	dn ^e
CMC 32	M	Seizures, GDD, hypotonia, sensorineural hearing loss	<i>DHRX</i>	c.643C>T / p.(L215F) (het ^f) [NM_145177]	mat ^e

			<i>DHRSY</i>	c.541G>T / p.(V181F) (het ^f) [NM_145177]	pat ^e
CMC 33	M	Arthrogryposis, hypotonia	<i>CAPRINI</i>	c.1338A>T / p.(Q446H) (het) [NM_005898]	dn
CMC 34	M	Neurodegenerative disorder, aplastic anemia	<i>KLHL12</i>	c.1700A>T / p.(D567V) (het) [NM_001303051]	dn
CMC 41	M	Congenital right cerebral hypoplasia, GDD/ID	<i>PLXNC1</i>	c.1400C>A / p.(A467D) (het) [NM_005761]	dn

CNS, central nervous system; dn, *de novo*; F, female; GDD, global developmental delay; hem, hemizygous; het, heterozygous; hom, homozygous; ID, intellectual disability; M, male; mat, maternal; MCA, multiple congenital anomalies; pat, paternal; SMMCI, solitary median maxillary central incisor syndrome; uk, unknown

^aMother does not have features of SMMCI on exam. We questioned whether there could be a gene–environment interaction with another risk factor present in this family (maternal type 1 diabetes mellitus).

^bClinVar Accession Number: VCV000426724.2 (same patient).

^cchr17:60628092_60637491del

^dNot inherited from mother.

^eVariant also present in similarly affected brother.

^fGene is within the pseudoautosomal region.